Q3: 2025-11-05 Earnings Summary
EPS of -$0.11 misses by $0.00
| Revenue of $12.81M (-5.43% Y/Y) misses by $136.50K
Aquestive Therapeutics, Inc. (AQST) Discusses Anaphylm Regulatory Progress, Commercial Strategy, and Pipeline Development November 6, 2025 12:00 PM EST
Company Participants
Daniel Barber - CEO, President & Director Melina Cioffi - Senior Vice President of Regulatory Affairs Cassie Jung - Chief Operating Officer Gary Slatko - Interim Chief Medical Officer Sherry Korczynski - Chief Commercial Officer Ernie Toth - Chief Financial Officer
Conference Call Participants
David Amsellem - Piper Sa…
Q3: 2025-11-05 Earnings Summary
EPS of -$0.11 misses by $0.00
| Revenue of $12.81M (-5.43% Y/Y) misses by $136.50K
Aquestive Therapeutics, Inc. (AQST) Discusses Anaphylm Regulatory Progress, Commercial Strategy, and Pipeline Development November 6, 2025 12:00 PM EST
Company Participants
Daniel Barber - CEO, President & Director Melina Cioffi - Senior Vice President of Regulatory Affairs Cassie Jung - Chief Operating Officer Gary Slatko - Interim Chief Medical Officer Sherry Korczynski - Chief Commercial Officer Ernie Toth - Chief Financial Officer
Conference Call Participants
David Amsellem - Piper Sandler & Co., Research Division
Presentation
David Amsellem Piper Sandler & Co., Research Division
All right. Well, good afternoon, everyone. This is David Amsellem from the Piper Sandler Biopharma research team. I know it’s a real busy day, and we’re trying to all get through the heart or really the tail end of the 3Q earnings cycle. We got a lot to cover, though, with Aquestive. And I think this will be a really informative and insightful hour that we’ll be spending with the Aquestive Therapeutics senior leadership team. And we really have the whole team here.
We’ve got Dan Barber, President and CEO; Ernie Toth, CFO; Gary Slatko, Chief Medical Officer; Melina Cioffi, SVP, Regulatory Affairs; Cassie Jung, Chief Operating Officer; and Sherry Korczynski, Chief Commercial Officer. So thanks so much to all of you for joining. I know many of you are at the ACAAI meeting down in Florida, and there will be data presented there in the coming days. So a big forum for all things Anaphylm.
Question-and-Answer Session
David Amsellem Piper Sandler & Co., Research Division
So with that, I wanted to turn it over to Dan just for a quick introduction. And also, I’ll start with, as I typically do with these things, a question. So with [indiscernible], also a question here, looking more broadly at the company. Obviously, Anaphylm and getting Anaphylm right is the top priority. But longer term, how do you balance that top priority with other clinical and commercial